

Jill M Kramer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2312384/publications.pdf>

Version: 2024-02-01

42
papers

1,161
citations

430874

18
h-index

395702

33
g-index

44
all docs

44
docs citations

44
times ranked

1496
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-17: A New Paradigm in Inflammation, Autoimmunity, and Therapy. <i>Journal of Periodontology</i> , 2007, 78, 1083-1093.	3.4	124
2	The IL-17 Cytokine Family. <i>Vitamins and Hormones</i> , 2006, 74, 255-282.	1.7	118
3	CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis. <i>Journal of Leukocyte Biology</i> , 2013, 94, 1079-1089.	3.3	116
4	Cutting Edge: Evidence for Ligand-Independent Multimerization of the IL-17 Receptor. <i>Journal of Immunology</i> , 2006, 176, 711-715.	0.8	99
5	Innate immunity in Sjögren's syndrome. <i>Clinical Immunology</i> , 2017, 182, 4-13.	3.2	76
6	Recent Advances in the Etiology and Treatment of Burning Mouth Syndrome. <i>Journal of Dental Research</i> , 2018, 97, 1193-1199.	5.2	57
7	Early events in Sjögren's Syndrome pathogenesis: The importance of innate immunity in disease initiation. <i>Cytokine</i> , 2014, 67, 92-101.	3.2	55
8	Current and Emerging Evidence for Toll-Like Receptor Activation in Sjögren's Syndrome. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	2.2	48
9	Cutting Edge: Identification of a Pre-Ligand Assembly Domain (PLAD) and Ligand Binding Site in the IL-17 Receptor. <i>Journal of Immunology</i> , 2007, 179, 6379-6383.	0.8	45
10	Molecular concepts in the pathogenesis of ameloblastoma: Implications for therapeutics. <i>Experimental and Molecular Pathology</i> , 2014, 97, 345-353.	2.1	35
11	Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction. <i>Clinical Immunology</i> , 2016, 164, 85-94.	3.2	34
12	Activation of Myd88-Dependent TLRs Mediates Local and Systemic Inflammation in a Mouse Model of Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 2963.	4.8	30
13	Myd88 is required for disease development in a primary Sjögren's syndrome mouse model. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1411-1420.	3.3	28
14	Systemic manifestations of primary Sjögren's syndrome in the NOD.B10Sn-H2J mouse model. <i>Clinical Immunology</i> , 2017, 183, 225-232.	3.2	25
15	Transcriptomic and Single-Cell Analysis of the Murine Parotid Gland. <i>Journal of Dental Research</i> , 2019, 98, 1539-1547.	5.2	24
16	Is it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 123, 482-495.	0.4	22
17	Transcriptomic and Network Analysis of Minor Salivary Glands of Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 606268.	4.8	21
18	Sebaceous Carcinoma In Situ. <i>American Journal of Dermatopathology</i> , 2010, 32, 854-855.	0.6	20

#	ARTICLE	IF	CITATIONS
19	The osteopontin transgenic mouse is a new model for Sjögren's syndrome. <i>Clinical Immunology</i> , 2015, 157, 30-42.	3.2	20
20	Transcriptomic and Single-Cell Analysis Reveals Regulatory Networks and Cellular Heterogeneity in Mouse Primary Sjögren's Syndrome Salivary Glands. <i>Frontiers in Immunology</i> , 2021, 12, 729040.	4.8	17
21	Is Monocyte Chemotactic Protein 1 Elevated in Aseptic Loosening of TKA?: A Pilot Study. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 1879-1884.	1.5	15
22	Fibromyxoma of the Jaw: Case Report and Review of the Literature. <i>Head and Neck Pathology</i> , 2018, 12, 44-51.	2.6	14
23	Clinicopathologic significance of in vivo antinuclear autoantibodies in oral mucosal biopsies. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 475-482.	0.4	13
24	Danger signals in oral cavity-related diseases. <i>Journal of Leukocyte Biology</i> , 2019, 106, 193-200.	3.3	13
25	Sjögren's Syndrome: Animal Models, Etiology, Pathogenesis, Clinical Subtypes, and Diagnosis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-3.	2.2	12
26	Immune-Intrinsic Myd88 Directs the Production of Antibodies With Specificity for Extracellular Matrix Components in Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 692216.	4.8	12
27	Calcifying aponeurotic fibroma with bone islands exhibiting hematopoiesis: a case report and review of the literature. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 109, 878-882.	1.4	10
28	Saliva-Microbe Interactions and Salivary Gland Dysfunction. <i>Advances in Dental Research</i> , 2014, 26, 7-14.	3.6	10
29	Tissue-specific activation of Myd88-dependent pathways governs disease severity in primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2021, 118, 102608.	6.5	9
30	Laugier-Hunziker Syndrome Presenting with Metachronous Melanoacanthomas. <i>Head and Neck Pathology</i> , 2019, 13, 257-263.	2.6	8
31	Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice. <i>Clinical Immunology</i> , 2014, 153, 79-90.	3.2	6
32	Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome. <i>Journal of Leukocyte Biology</i> , 2016, 99, 321-331.	3.3	6
33	Sera and salivary matrix metalloproteinases are elevated in patients with vesiculoerosive disease: a pilot study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 520-529.	0.4	5
34	Current concepts in Sjögren's syndrome and considerations for the dental practitioner. <i>New York State Dental Journal</i> , 2015, 81, 24-9.	0.2	4
35	Bisphosphonates and Osteonecrosis of the Jaws: A Review of Clinical Features and the Drug Effect on Oral Soft Tissues. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2011, 9, 38-46.	0.8	3
36	T24 HRAS transformed NIH/3T3 mouse cells (GhrasT-NIH/3T3) in serial tumorigenic in vitro/in vivo passages give rise to increasingly aggressive tumorigenic cell lines T1-A and T2-A and metastatic cell lines T3-HA and T4-PA. <i>Experimental Cell Research</i> , 2016, 340, 1-11.	2.6	3

#	ARTICLE	IF	CITATIONS
37	A large calcifying lesion of the maxilla in a child. Journal of the American Dental Association, 2011, 142, 1026-1030.	1.5	2
38	Matrix Metalloproteinase in Oral Vesiculoerosive Disease—Analysis and Therapeutic Modulation With Subantimicrobial Dose Doxycycline: A Pilot Study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, e493-e494.	0.4	0
39	Analysis of biglycan in salivary tissue: implications for Sjogren's syndrome. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, e196.	0.4	0
40	Does it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms—Response. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 506.	0.4	0
41	Innate Immune Dysregulation in Sjögren's Syndrome. , 2021, , 71-93.		0
42	Subunit Dynamics in the IL-17 Receptor Complex: Identification of a Pre-ligand Assembly Domain (PLAD) and Ligand Binding site in IL-17RA. FASEB Journal, 2008, 22, 1069.1.	0.5	0